Thr182
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr182  -  MAPKAPK5 (mouse)

Site Information
VDQGDLMtPQFTPYY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450093

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 10 ) , immunoprecipitation ( 6 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 7 , 8 , 9 ) , mutation of modification site ( 10 ) , phospho-antibody ( 6 ) , western blotting ( 6 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 1 ) , 'brain, embryonic' ( 3 , 8 ) , 293 (epithelial) ( 10 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 10 ) , brain ( 4 , 7 ) , COS (fibroblast) ( 10 ) , HeLa (cervical) ( 10 ) , liver ( 5 , 9 ) , MEF (fibroblast) ( 6 )

Upstream Regulation
Putative in vivo kinases:
P38B (mouse) ( 6 )
Treatments:
2-deoxyglucose ( 6 ) , acadesine ( 6 ) , glucose_starvation ( 6 )

Downstream Regulation
Effects of modification on MAPKAPK5:
acetylation ( 2 ) , enzymatic activity, induced ( 10 ) , intracellular localization ( 10 ) , phosphorylation ( 6 )

References 

1

Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6
26060331   Curated Info

2

Zheng H, et al. (2013) A Posttranslational Modification Cascade Involving p38, Tip60, and PRAK Mediates Oncogene-Induced Senescence. Mol Cell 50, 699-710
23685072   Curated Info

3

Guo A (2011) CST Curation Set: 12476; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

4

Guo A (2011) CST Curation Set: 12477; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

5

Guo A (2011) CST Curation Set: 12478; Year: 2011; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

6

Zheng M, et al. (2011) Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nat Cell Biol 13, 263-72
21336308   Curated Info

7

Zhou J (2008) CST Curation Set: 4863; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

8

Zhou J (2008) CST Curation Set: 4864; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

9

Zhou J (2008) CST Curation Set: 4866; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

10

Seternes OM, et al. (2002) Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. Mol Cell Biol 22, 6931-45
12242275   Curated Info